This therapeutic radiopharmaceutical had shown promising preclinical data with significantly higher tumor uptake and improved tumor-to-normal organ ratio compared to the clinically used SSTR2 agonists like 177Lu-DOTA-TATE (Lutathera) 21-24. The gene discussed is SSTR2; the disease is neoplasm.